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Histopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis
have not been studied. We aimed to describe the characteristics, focusing on histopathol-
ogy, of idiopathic pulmonary fibrosis patients who did and did not respond to nintedanib.
Methods
This study retrospectively examined the clinicoradiopathologic features of 40 consecutive
patients with surgical lung biopsy-confirmed idiopathic pulmonary fibrosis treated with ninte-
danib. Additionally, we compared the histopathologic scoring of 21 microscopic features
between patients with functional or radiological progression and those with non-progression
during 12 months of treatment.
Results
The histopathologic evaluation showed edematous changes in the interlobular septum as
the only histologic finding observed more frequently in patients with both functional and
radiological progression than in those without (58% vs. 14%, P = 0.007 and 50% vs. 0%, P =
0.003, respectively). Regarding per-year change, patients with edematous changes in the
interlobular septum showed greater progression in median changes in spared area (-12%,
interquartile range: [-25%–-5%], vs. -3% [-7%–0%], P = 0.004) and reticular shadow (7%
[3%–13%], vs. 0% [0%–5%], P = 0.041) on computed tomography. Functional and radiologi-
cal progression-free survival were shorter in patients with edematous changes in the inter-
lobular septum than in those without (6.6 months, 95% confidence interval: [5.9–25.3], vs.
event <50%, [12.1–Not available], P = 0.0009, and 6.1 months, [5.2–6.6] vs. 14.5 months
[7.8–not available], P<0.0001).
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Conclusions
Edematous changes in the interlobular septum may indicate poor nintedanib efficacy in idio-
pathic pulmonary fibrosis. Further studies are needed to validate these findings and address
the mechanism behind ECIS.
Introduction
Predictive biomarkers of nintedanib efficacy in patients with idiopathic pulmonary fibrosis
(IPF) have not been addressed previously but are urgently needed for optimal clinical out-
comes. As a study of serum markers is already underway [1], a histopathological investigation
is of equal importance. IPF is a severe progressive fibrotic disease of unknown cause that
results in intractable dyspnoea upon exertion. The disease has a reported median overall sur-
vival period of 30 months—a time comparable to that of stage III non-small cell lung cancer
[2, 3].
Alveolar epithelium and fibroblasts are thought to be key players in the pathogenesis of IPF
because recurrent epithelial injury (EI) leads to aberrant repair of the injured alveoli and depo-
sition of interstitial fibrous tissue by myofibroblasts [4]. The 2015 updates to the American
Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin
American Thoracic Association IPF treatment guidelines list antifibrotic agents, such as ninte-
danib and pirfenidone, as conditional recommendations [5]. Nintedanib is a triple tyrosine
kinase inhibitor that targets vascular endothelial, fibroblast, and platelet-derived growth factor
receptors [4]. Results from a phase 3 clinical trial [6] and a meta-analysis [7] indicated that nin-
tedanib lessens the decline in forced vital capacity (FVC); prospective cohort studies [7, 8] also
demonstrated that nintedanib therapy is associated with a lower rate of acute exacerbation and
a lower hazard ratio (HR) for all-cause deaths. The development of effective treatments has
stressed the need for timely and accurate diagnosis because of the heterogeneity of IPF and the
ability of other interstitial pneumonias to mimic IPF [4]. Thus, multidisciplinary discussions
are important for accurate diagnosis and better patient prognosis [9].
Another clinical problem associated with IPF is its unpredictable response to antifibrotic
treatment. Although antifibrotics showed a 50% reduction of FVC decline in 1 year, compared
with the placebo group in a phase 3 trial and recent network meta-analysis, the individual
response to antifibrotics is unpredictable [6, 10]. Predictive biomarkers for antifibrotic treat-
ment should be elucidated to establish better treatment strategies. Although biomarkers of dis-
ease stability and pathological prognostic factors have been identified [2, 11–14], few studies
have investigated predictive factors of IPF treatment outcomes [15]; even fewer have examined
pathological specimens.
Thus, the aim of this study was to describe the histopathologic characteristics of patients
with IPF who did and did not respond to nintedanib treatment.
Materials and methods
Study patients
Consecutive patients with IPF, who started nintedanib (200 or 300 mg/day) treatment by Janu-
ary 2017, were retrospectively identified from electronic medical records at two tertiary care
hospitals. IPF was diagnosed by a multidisciplinary team using multimodal information,
including chest computed tomography (CT) scans and surgical lung biopsy (SLB) findings.
The exclusion criteria were: (1) loss to follow-up within 6 months from starting nintedanib
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treatment; (2) concomitant medication (e.g., systemic glucocorticosteroids, immunosuppres-
sants, or pirfenidone) use when starting nintedanib treatment; (3) missing data within 6
months prior to starting nintedanib treatment and at 12 months after the start of nintedanib
treatment, except for cases of death or acute exacerbation; and (4) unresectable lung cancer.
Study design
This was a two-centre, retrospective, cohort study of patients with IPF in Japan that assessed
the characteristics of patients with IPF who did and did not demonstrate functional or radio-
logical progression. Functional progression was defined as the presence of indicators based
on the following composite factors after 12 months of nintedanib treatment: 1) all-cause
death; 2) acute exacerbation, reported by pulmonary physicians; 3) relative FVC decline of
�10% [16]. Radiological progression was defined similarly: 1) all-cause death; 2) acute
exacerbation; and 3) relative change in the extent of reticular opacity or honeycombing
(HC), or reduction in the extent of normal lung area on chest CT scans of �10%. Functional
and radiological progression included all-cause death and acute exacerbation to avoid com-
peting-risk bias and was defined as fulfilment of at least one of the composite progression
criteria; failure to fulfil any of the criteria was classified as non-progression. The study design
and reporting adhered to the Strengthening the Reporting of Observational Studies in Epide-
miology Statement [17]. The institutional review boards of both hospitals (Kameda Medical
Center, Kamogawa, Japan, and Tosei General Hospital, Seto, Japan) approved the study and
waived the need for written informed consent from the study patients. (Approval no.: 17–
089 and 674, respectively).
Data sources and measurements
Baseline clinical, pulmonary function test (PFT), and chest CT data were obtained from the
electronic medical records of both hospitals. Clinical data included patient age, sex, smoking
status, and comorbid diseases. PFT and chest CT data were obtained before the start of ninte-
danib treatment (within 3 months), as well as at a variable point of 6 to 12 months after starting
nintedanib treatment.
Chest CT scans were obtained with 1- or 2-mm collimation at 1- or 10-mm intervals and
fitted under a high spatial frequency algorithm. Two blinded board-certificated chest radiolo-
gists, with 30 and 16 years of experience reviewed the chest CT data. The images were indepen-
dently evaluated to score the extent of reticular opacity, HC, traction bronchial-
bronchiolectasis, ground-glass opacity, airspace consolidation, cyst formation, emphysema
(Em), and spared lung area in gradations of 5%, as previously described by Fujisawa et al. [18].
Consensus was established when the numerical difference between the evaluations differed by
�10%; the inter-rater variability was assessed.
Histological evaluation
Whole-section SLB specimens were stained using haematoxylin and eosin and Elastica van
Gieson or Elastica–Masson staining. All evaluations were performed using digitized images by
slide scanners at 20× magnification (Aperio CS, Sausalito, CA, USA or VS100, Olympus,
Tokyo, Japan). The SLB images were independently evaluated by four board-certificated pul-
monary pathologists, with 9–24 years of experience, blinded to the clinical data. The histopath-
ological findings were rated from 0 to 3 points (0, absent; 1, weak; 2, moderate; and 3, strong)
and further dichotomized as negative (0–1 points) or positive (2–3 points). Consensus was
established when the positive or negative judgements were discrepant among the reviewers;
the inter-rater variability was assessed. The histopathological findings of interest (total– 21
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features) were: dense fibrosis (DF), cellular interstitial pneumonia, marked organizing pneu-
monia, fibroblastic focus (FF), destroyed architecture (DA), HC, smooth muscle hyperplasia,
elastosis, lymphoid follicles, cellular/fibrinous pleuritis, plasma cell infiltration, constrictive
bronchiolitis, vascular intimal thickness, loose granuloma, interstitial giant cells, peribronchio-
lar metaplasia, airway-centred changes, EI, Em, alveolar exudate, and edematous changes in
the interlobular septum (ECIS). All pathologists had a group session to standardize the mor-
phologic features prior to their review of the study specimens.
Statistical analysis
Baseline clinical characteristics and histological and radiological data were expressed as
descriptive statistics. The study outcome was analysed relative to each variable. Progression-
free survival (PFS) was calculated from the first day of nintedanib treatment until progression
status assessments at both the 6- and 12-month time points. The χ2 test was performed to ana-
lyse categorical variables and the Mann–Whitney U test was performed to analyse continuous
variables. Logistic regression analysis was performed as multivariate analysis. Statistical signifi-
cance was indicated by a P-value <0.05. All analyses were performed using the R statistical
software package (version 3.5.2, R Foundation for Statistical Computing, Vienna, Austria)




A total of 131 patients with IPF were undergoing treatment with nintedanib at the study hospi-
tals by January 2017. After excluding 62 patients without SLBs, 12 receiving combination ther-
apy with an immunosuppressant, eight with SLBs performed at other hospitals, six with
misdiagnoses, two who discontinued nintedanib treatment within 1 month, and three with
unresectable lung cancer, 40 patients ultimately met the study criteria (Fig 1, S1 Dataset). All
40 SLBs were performed in multiple lobes including the lower lobe. The baseline characteris-
tics of the 40 patients are presented in Table 1.
Median age was 66 years and 32 (80%) patients were men; the median time from diagnosis
to nintedanib administration was 2.3 years (range: 0.1–7.4 years). In the study cohort, 19
(48%) and 28 (70%) patients exhibiting all-cause death, acute exacerbations, relative FVC
decline, or disease progression on chest CT scans in 12 months were defined to have functional
or radiological progression, respectively.
Histopathological characteristics
Histopathologically, most SLB specimens showed DF (83%), DA (75%), FF (50%), and HC
(40%), which suggested a specific usual interstitial pneumonia pattern (Table 2) [20]. In com-
parison with each non-progression group, ECIS (demonstrated in Fig 2) was predominantly
observed in patients with functional progression (58%, P = 0.007) and was only observed in
patients with radiological progression (50%, P = 0.003); otherwise, only 14% and 0% of
patients without functional and radiological progression, respectively, showed ECIS. No histo-
pathological findings were significantly different between the progression and non-progres-
sion groups. The inter-rater variability kappa value for all histopathological scores (judged as
negative [0–1 points] or positive [2–3 points]), showed moderate agreement (κ = 0.48), includ-
ing those for ECIS (κ = 0.50). There were no statistical differences in the frequencies of any his-
tological findings between patients with and without ECIS (S1 Table).
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Fig 1. Patient selection flow chart.
https://doi.org/10.1371/journal.pone.0245147.g001
Table 1. Patients characteristics.
Characteristics Study cohort (n = 40)
Age, median, years (IQR) 66 (64, 70)
Men, n (%) 32 (80)
Smoking status, n (%)
Non-smoker 10 (25)
Former smoker 29 (73)
Current smoker 1 (3)
Brinkman index, median (IQR) 600 (75, 1028)
Specimen from surgical lung biopsy available, % 100
Median years from diagnosis to nintedanib administration (range) 2.3 (0.1–7.4)
Forced vital capacity
Median, L (IQR) 2.11 (1.93, 2.66)
Percentage of predicted value, median, % (IQR) 74 (66, 88)
Diffusing capacity of the lung for carbon monoxide
Median, mmol/min/kPa (IQR) 9.6 (8.1, 12.5)
Percentage of predicted value, median, % (IQR) 56 (49, 65)
Functional progression, n (%) 19 (48)
Radiological progression, n (%) 28 (70)
IQR, interquartile range; Brinkman index calculated as the number of cigarettes smoked per day multiplied by the
number of years smoked.
https://doi.org/10.1371/journal.pone.0245147.t001
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Table 2. Histological findings of surgical lung biopsy specimens.
Pathological findings All patients Functional progression P-value Radiological progression P-value
n = 40 (%) Yes No Yes No
n = 19 n = 21 n = 28 n = 12
(%) (%) (%) (%)
Dense fibrosis 33 (83) 18 (86) 15 (79) 0.689 22 (79) 11 (92) 0.652
Cellular interstitial pneumonia 2 (5) 2 (11) 0 (0) 0.219 2 (7) 0 (0) 1
Marked organizing pneumonia 2 (5) 0 (0) 2 (10) 0.488 0 (0) 2 (17) 0.085
Fibroblastic focus 20 (50) 10 (53) 10 (48) 1 13 (46) 7 (58) 1
Destroyed architecture 30 (75) 14 (74) 16 (76) 1 19 (68) 11 (92) 0.231
Honeycombing 16 (40) 6 (32) 10 (48) 0.349 10 (36) 6 (50) 0.490
Smooth muscle hyperplasia 12 (30) 6 (32) 6 (29) 1 6 (21) 6 (50) 0.130
Elastosis 7 (18) 3 (16) 4 (19) 1 5 (18) 2 (17) 1
Lymphoid follicles 4 (10) 2 (11) 2 (10) 1 2 (7) 2 (17) 0.570
Cellular/fibrinous pleuritis 0 (0) 0 (0) 0 (0) NA 0 (0) 0 (0) NA
Plasma cell infiltration 2 (5) 2 (11) 0 (0) 0.219 2 (7) 0 (0) 1
Constrictive bronchiolitis 2 (5) 2 (11) 0 (0) 0.219 2 (7) 0 (0) 1
Vascular intimal thickness 6 (15) 2 (11) 4 (19) 0.664 4 (14) 2 (17) 1
Loose granuloma 0 (0) 0 (0) 0 (0) NA 0 (0) 0 (0) NA
Interstitial giant cell 1 (3) 1 (5) 0 (0) 0.475 1 (4) 0 (0) 1
Peribronchiolar metaplasia 16 (40) 6 (32) 10 (48) 0.349 11 (39) 5 (42) 1
Airway-cantered changes 3 (8) 1 (5) 2 (10) 1 1 (4) 2 (17) 0.209
Epithelial injury 7 (18) 3 (16) 4 (19) 1 6 (21) 1 (8) 0.652
Alveolar exudate 4 (10) 2 (11) 2 (10) 1 3 (11) 1 (8) 1
Edematous changes in the interlobular septum 14 (35) 11 (58) 3 (14) 0.007 14 (50) 0 (0) 0.003
NA, not available.
https://doi.org/10.1371/journal.pone.0245147.t002
Fig 2. Representative image of edematous changes in the interlobular septum (ECIS) from a surgical lung biopsy sample. (A, B) and (C, D) are two
cases of ECIS with remarkable oedema and interlobular septal thickening. The dilated lymph vessels (arrowheads) support the presence of an oedema as
a true finding and not an air contamination during the specimen preparation. (E, F) are images of a patient without ECIS. (A, C, E, and F)
Haematoxylin and eosin staining. (B, D) Elastica van Gieson staining. The black bars show the magnification.
https://doi.org/10.1371/journal.pone.0245147.g002
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Baseline characteristics and outcomes
The baseline characteristics of patients with and without ECIS are presented in Table 3. In the
univariate analysis, patients with ECIS were older than patients without it (median 68 vs. 66
years, P = 0.014); moreover, patients with ECIS had a higher female-to-male ratio (43% vs.
11%, P = 0.044), lower %DLCO (median 55% vs. 61%, P = 0.050), lower extent of spared area
on chest CT (median 54% vs. 63%, P = 0.050), and marginally significantly greater proportion
of honeycomb pattern on chest CT (median 5% vs. 0%, P = 0.051). Multivariate analysis
including sex, age, the proportion of honeycomb pattern on chest CT, and initial %DLCO
revealed that only age and sex had statistically significant correlation to patients with ECIS.
Functional and radiological PFS were both significantly shorter in patients with ECIS than
in those without (6.6 months, 95% confidence interval [CI]: 5.9–25.3, vs. event <50%, 95% CI:
12.1–not available [NA], respectively, P = 0.0009, and 6.1 months, 95% CI: 5.2–6.6, vs. 14.5
months, 95% CI: 7.8–NA, respectively, P<0.0001). Kaplan–Meier curves and comparisons of
outcomes for both groups are shown in Fig 3 and Table 4, respectively. There were no signifi-
cant differences in the numbers of all-cause deaths and acute exacerbations between ECIS and
non-ECIS groups. The 12-month progression in PFT and chest CT showed significant
Table 3. Comparison of baseline characteristics in patients with or without ECIS in univariate and multivariate analysis.
Characteristic With ECIS Without ECIS P-value
n = 14 n = 26
Age, median, years (IQR) 68 (66, 73) 66 (63, 67) 0.014
Men, No. (%) 8 (57) 23 (89) 0.044
Body mass index (IQR) 24 (23, 28) 23 (21, 26) 0.335
Smoking status, No. (%)
Never/Former/Current smoker 5 (36)/9 (64)/0 (0) 5 (19)/20 (77)/1 (4) 0.640
Brinkman index, median (IQR) 400 (0, 760) 675 (183, 1133) 0.258
Median years from diagnosis to nintedanib administration (range) 2.5 (0.1 to 7.4) 1.4 (0.1 to 5.6) 0.364
Forced vital capacity, median, L (IQR) 2.20 (2.03, 2.76) 2.08 (1.92, 2.60) 0.379
Percentage of predicted value, median, % (IQR) 74 (66, 83) 73 (66, 80) 0.843
Diffusing capacity of the lung for carbon monoxide
Median, mmol/min/kPa (IQR) 9.49 (8.39, 11.69) 10.34 (8.84, 13.82) 0.363
Percentage of predicted value, median, % (IQR) 55 (44, 61) 61 (55, 69) 0.050
Distance in the 6-minute walk test, median, m (IQR) 510 (424, 576) 528 (470, 615) 0.278
Serum KL-6, median, U/mL (IQR) 1306 (911, 1851) 1235 (910, 1930) 0.921
Initial CT evaluation, median % (IQR)
Spared area 54 (44, 58) 63 (50, 72) 0.050
Reticular opacity 24 (17, 28) 16 (13, 24) 0.122
Honeycomb 5 (0, 7) 0 (0, 3) 0.051
Traction bronchial -bronchiolectasis 12 (7, 14) 11 (7, 14) 0.921
Cyst and emphysema 0 (0, 6) 2 (0, 5) 0.509
Ground-glass opacity and air-space consolidation 9 (7, 13) 8 (5, 11) 0.232
Multivariate analysis
Characteristic Odds ratio 95% confidence interval P-value
Age 1.31 1.01–1.70 0.040
Sex 12.1 1.17–126.00 0.037
Diffusing capacity of the lung for carbon monoxide 1.02 0.998–1.050 0.071
Honeycomb in initial CT evaluation 0.89 0.66–1.18 0.411
CT, computed tomography; IQR, interquartile range; ECIS, edematous changes in the interlobular septum; KL-6, Krebs von den Lungen-6.
https://doi.org/10.1371/journal.pone.0245147.t003
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differences, and chest CT showed a significant decrease in normal lung area and an increase in
the reticular shadow in patients with ECIS. In particular, the median rate of spared area
decrease within 12 months was -12% (interquartile range [IQR]: -25%–-5%) of whole-lung
volume in patients with ECIS, compared with -3% (IQR: -7%–0%) in patients without ECIS
(P = 0.004). The median rate of reticular shadow increase within 12 months was 7% (IQR:
3%–13%) in patients with ECIS, compared with 0% (IQR: 0%–5%) in patients without ECIS
(P = 0.041). The inter-rater variability kappa value for the assessment of radiological progres-
sion showed high agreement (κ = 0.75).
Fig 3. Kaplan–Meier curves for functional (A) and radiological (B) progression-free survival in patients with or without edematous changes in the
interlobular septum (ECIS). Both curves (A and B) showed statistical differences (P<0.001 in both).
https://doi.org/10.1371/journal.pone.0245147.g003
Table 4. Outcome comparison in patients with or without ECIS.
Outcomes All patients With ECIS Without ECIS P-value
n = 40 n = 14 n = 26
All-cause death within 12 months, n (%) 5 (13) 1 (7) 4 (15) 0.640
Acute exacerbation within 12 months, n (%) 5 (13) 3 (21) 2 (8) 0.322
Functional progression, n (%) 19 (48) 11 (79) 8 (31) 0.007
Radiological progression, n (%) 28 (70) 14 (100) 14 (54) 0.003
Change in FVC within 12 months, median, ml (IQR) -30 (-210, 120) -180 (-690, 90) 40 (-112, 125) 0.124
Change of spared area on CT within 6 months, median, % (IQR) -2 (-10, 0) -7 (-17, -2) 0 (-4, 0) 0.009
Change of spared area on CT within 12 months, median, % (IQR) -5 (-12, -2) -12 (-25, -5) -3. (-7, 0) 0.004
Change of honeycomb on CT within 6 months, median, % (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.462
Change of honeycomb on CT within 12 months, median, % (IQR) 0 (0, 0) 0 (0, 3) 0 (0, 0) 0.187
Change of reticular shadow on CT within 6 months, median, % (IQR) 0 (0, 5) 3 (2, 10) 0 (0, 1) 0.001
Change of reticular shadow on CT within 12 months, median, % (IQR) 3 (0, 8) 7 (3, 13) 0 (0, 5) 0.041
CT, computed tomography; FVC, forced vital capacity; IQR, interquartile range; ECIS, edematous changes in the interlobular septum.
https://doi.org/10.1371/journal.pone.0245147.t004
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Discussion
This study described the characteristics of patients with IPF undergoing nintedanib treatment,
including histopathological findings associated with poor response to therapy. We found that
most patients developed functional and radiological progression during the 12-month follow-
up period. In patients showing disease progression, ECIS in SLB specimens was significantly
more frequently observed; very few patients without functional and radiological progression
showed ECIS. In patients with ECIS, PFS was significantly shorter.
To the best of our knowledge, our study is the first to report the histopathological character-
istics of patients with IPF who did not respond to nintedanib treatment; we also determined
ECIS as an important predictive marker of disease progression. Although the evaluation of
some pathological findings is challenging and the level of diagnostic agreement of IPF in previ-
ous reports has been very low (κ-values = 0.21 to 0.37) [21–23], the κ-values of interobserver
agreement among expert pathologists in the current study remained within the permissive
range (κ = 0.48).
According to previous publications, 24–30% of IPF patients with nintedanib developed pro-
gression at a rate similar to that of patients without any treatment and showed reduced FVC
values during treatment [10]. The current study demonstrated a more frequent progression
rate because eligible patients had advanced disease. The surgical lung biopsy itself might cause
the increase of acute exacerbation, however the progression-time analysis (Fig 3) showed that
there were no patients with acute exacerbation in the first four months after the biopsy. To
select study participants, we included patients from the inception of nintedanib administration
until January 2017; the median duration of nintedanib administration from the diagnosis of
IPF was 2.3 years. Thus, the initial CT evaluation revealed that the median extent of spared
area was only 54% in patients with ECIS and 63% in those without ECIS. Even under such cir-
cumstances, a notable histological finding of ECIS was predictive of disease progression during
nintedanib therapy, especially in the radiological progression group.
To ensure that ECIS was not artifactually induced, we matched tissue processing protocols
at both institutions and found that the stepwise specimen processing and reagents used were
the same. We also consistently observed dilated lymphatics associated with ECIS (Fig 2),
which proved that an edema was a true finding and not an air contamination during the speci-
men preparation. The background aetiology of ECIS is uncertain. It is one of the histological
findings in pulmonary edema; the underlying aetiology of permeability edema has been
reported in addition to other mechanisms, such as inhalant toxicity, primary alveolar proteino-
sis, pulmonary veno-occlusive disease, traumatic lung injury, or acute respiratory distress syn-
drome. Moreover, it is regarded as a manifestation of lymphovascular disorder in the
interstitium or alveolar damage [24–28]. If alveolar capillary damage persists, leakage of the
protein-rich fluid from the intravascular space into the interstitium may progress and eventu-
ally induce pulmonary fibrosis [29]. Furthermore, ECIS may cause uneven distribution of
blood in the lung, which hinders effective drug delivery. In the perspective of respiratory func-
tion, the DLco showed slightly high odds ratio for the existence of ECIS in multivariate analy-
sis. This might support the uneven distribution of blood in the lungs. or suggest the
coexistence of pulmonary hypertension. Although we could not access full clinical informa-
tion, the pathological subanalysis did not show the significance of vascular intimal thickness in
patients with ECIS. The presence of ECIS may explain the subtypes of IPF not promoted by
the major genetic determinants, such as airway mucin gene family, MUC5B or MUC2 [11], but
by some factors related to the inflammatory response. Further studies are needed for better
pathological understanding of ECIS in patients with IPF and for correlation with other clinical
biomarkers, such as bronchoalveolar lavage fluid, right heart catheter, and so on.
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This study had some limitations that should be addressed. First, this was a two-centre study
based on a relatively limited sample size due to the rare prevalence of the disease [30] and strict
participant inclusion and exclusion of only those precisely diagnosed with SLB through multi-
disciplinary discussion and carefully followed up with multiple PFTs and chest CT scans
around 12 months after the nintedanib initiation. Second, this was a retrospective investigation
that lacked a control group. Therefore, we cannot exclude the efficacy of nintedanib, even in
the progressive disease group. Additionally, switch to or combination with the alternative ther-
apy (e.g., pirfenidone or immunosuppressants) is another important issue in the progressive
group that requires further investigation. Third, the observation period in this study was not
designed to investigate the difference in survival, as this requires more time; however, it was
sufficient for analysing PFS. In addition, it is notable that both functional and radiological pro-
gression included the five patients with all-cause death and acute exacerbation for reducing
the survivor bias. Fourth, this retrospective cohort without controls could not eliminate the
biases and confounders. On the other hand, the fact that no patient without ECIS showed dis-
ease progression gave sufficient power to waive multivariate analysis. Last, it has additional
impact to specify clinical biomarkers or radiological character for efficacy prediction of ninte-
danib for the clinical use than for histopathological one. The current results could help eluci-
date what causes progression in IPF despite anti-fibrotic regimens and make correlations with
clinical biomarkers for treatment efficacy prediction.
Conversely, the strengths of the study are obvious. It is the first of its kind to examine in
detail the histopathological changes (21 parameters scored semiquantitatively) of IPF patients
treated with nintedanib. We found that ECIS, a previously underappreciated histological find-
ing, was correlated with poor prognosis in the study cohort. Hence, certain histopathologic
parameters might be of prognostic significance and a careful evaluation of SLB during IPF
treatment should be considered.
In conclusion, the current study described characteristics of patients with SLB-confirmed
IPF who demonstrated disease progression during nintedanib treatment. ECIS was the key fac-
tor predictive of poor treatment efficacy contributing to shortened PFS. Further studies involv-
ing larger series of patients are needed to validate the factors predictive of nintedanib efficacy.
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